MedTrace Logo

Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

NCT00495170 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2019-02-06

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if proton radiotherapy given with standard chemotherapy (such as paclitaxel and carboplatin) can help to control locally advanced NSCLC. The safety of this treatment will also be studied.

Conditions

Interventions

DRUG

Carboplatin

2 area under curve (AUC) by vein Weekly

RADIATION

Proton Radiotherapy

2 GY/fraction for 37 fractions (daily treatment, Monday to Friday, for 7.5 weeks).

DRUG

Paclitaxel

50 mg/m\^2 by vein Weekly

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Joe Y. Chang, MD, PhD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-14
Primary Completion
2017-06-14
Completion
2017-06-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00495170 on ClinicalTrials.gov